The compound, named PROLENSA, was developed by recently acquired ISTA Pharmaceuticals.
“The PROLENSA filing is an important step towards bringing safe, effective and meaningful medical advances to medical professionals and their patients,” said Marvin Garrett, vice president of U.S. regulatory affairs, quality assurance and compliance for Bausch + Lomb, in the release. “It’s also a timely example of the progress we continue to make on critical D&R programs as we work to bring together the best of ISTA Pharmaceuticals and Bausch + Lomb.”
Related Articles on FDA Clearances:
Medtronic Receives Expanded FDA Clearance for Pillar Palatal Implant System
St. Jude Receives FDA Clearance for Ultrasound Catheter
Kimberly-Clark Health Care Receives FDA Clearance for Sterilization Wrap Portfolio
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
